AERI:NSD-Aerie Pharmaceuticals Inc.

EQUITY | Drug Manufacturers | NASDAQ Global Market

Last Closing Price

USD 57.90

Change

+0.50 (+0.87)%

Market Cap

USD 2.13B

Volume

0.23M

Yahoo Analyst Target

USD 79.75 (37.74%)

STA Analyst Target

USD 70.91 (22.47%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is engaged in the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-01-18 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Price(Change) Market Cap
WBA Walgreens Boots Alliance Inc.

+0.22 (+0.29%)

USD 75.29B
MYL Mylan N.V.

-0.27 (-0.58%)

USD 24.95B
NBIX Neurocrine Biosciences Inc.

+2.68 (+3.53%)

USD 6.95B
HCM Hutchison China MediTech Limit..

+0.25 (+0.63%)

USD 5.28B
AKRX Akorn Inc.

-0.09 (-0.27%)

USD 4.13B
GWPH GW Pharmaceuticals Plc

-0.45 (-0.34%)

USD 3.35B
HZNP Horizon Pharma plc

+0.22 (+1.47%)

USD 2.49B
IRWD Ironwood Pharmaceuticals Inc.

+0.10 (+0.67%)

USD 2.25B
SUPN Supernus Pharmaceuticals Inc.

-2.95 (-6.34%)

USD 2.23B
MDCO The Medicines Company

-0.34 (-1.34%)

USD 1.82B

ETFs Containing AERI

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers)
Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.10% 21% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.10% 21% F 17% F
Trailing 12 Months  
Capital Gain 36.88% 72% C- 76% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 36.88% 72% C- 75% C
Trailing 5 Years  
Capital Gain N/A 100% A+ 100% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A 100% A+ 100% A+
Average Annual (5 Year Horizon)  
Capital Gain N/A 100% A+ 100% A+
Dividend Return N/A 100% A+ 100% A+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A 1% F N/A N/A
Risk Adjusted Return 48.42% 87% B+ 54% F
Market Capitalization 1.30B 88% B+ 81% B-

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers)
Ratio vs. Market
(NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -17.28 91% A- 87% B+
Price/Book Ratio 11.40 17% F 10% F
Price / Cash Flow Ratio -5.54 92% A- 92% A-
Price/Free Cash Flow Ratio -20.90 93% A 87% B+
Management Effectiveness  
Return on Equity -86.86% 30% F 12% F
Return on Invested Capital -44.39% 54% F 19% F
Return on Assets -41.89% 49% F 16% F
Debt to Equity Ratio 102.25% 26% F 24% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.